X4 Pharmaceuticals Lands $150M Debt Deal with K2 HealthVentures
X4 Pharmaceuticals secured a senior debt facility worth up to $150 million, replacing its prior loan and extending its financial runway.
X4 Pharmaceuticals has entered into a senior secured debt facility with K2 HealthVentures valued at up to $150 million, the company announced, marking a significant restructuring of its capital base. As part of the arrangement, X4 has fully repaid its existing loan facility, eliminating that financial obligation and replacing it with the new agreement.
The fresh credit line is designed to bolster the biotech firm's financial flexibility, providing capital that management expects to deploy toward both corporate operations and commercial activities. The deal signals continued investor interest in the company's clinical pipeline at a time when smaller biotechs face heightened scrutiny over their funding positions.
Read more Oratomic Secures $775M to Develop Fault-Tolerant Quantum Computers →
Central to that pipeline is the Phase 3 4WARD trial, which X4 said it anticipates completing enrollment by the end of 2026. Topline data from that study is projected to arrive in the first half of 2028, a timeline that gives the company a defined runway to execute on its late-stage development goals.
The K2 HealthVentures facility provides X4 with staged access to capital, a structure common in life-sciences lending that ties disbursements to clinical or operational milestones. Such arrangements can preserve equity while giving companies the liquidity needed to advance high-cost drug development programs through pivotal trials.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
